New Report Available: Serbia Pharmaceuticals & Healthcare Report Q4 2013
Despite per capita expenditure on drugs increasing considerably towards the end of the last decade, Serbia's pharmaceutical market as a whole is underdeveloped in regional terms, having suffered as a result of political and economic instability.. As the country continues its economic convergence with developed Europe, drug consumption is also expected to rise. However, financial inefficiencies within the health insurance system mean that the National Health Insurance Institution (RZZO) is unable to always meet its obligations on time, with frequent...
View full press release